Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

Digestive Diseases and Sciences

Volumn 60, Issue 1, 2015, Pages 260-268

  Tsai, Naoky C ^a   Marcellin, Patrick ^b   Buti, Maria ^c   Washington, Mary Kay ^d   Lee, Samuel S ^e   Chan, Sing ^f   Trinh, Huy ^g   Flaherty, John F ^h   Kitrinos, Kathryn M ^h   Dinh, Phillip ^h   Charuworn, Prista ^h   Subramanian, G Mani ^h   Gane, Edward ⁱ  

^a UNIVERSITY OF HAWAII   (United States)

^b BEAUJON HOSPITAL   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f Private Practice   (United States)

^g San Jose Gastroenterology   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Antiviral agent; Asian; Chronic hepatitis B; Liver cirrhosis; Tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; BONE DENSITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HUMAN; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; RISK FACTOR;

ADENINE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MALE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 84920518409     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3336-7     Document Type: Article

References (24)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219.
2. World Health Organization. Hepatitis B: fact sheet no. 204 2013, July 2013. http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
4. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683.
5. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has reveal revealed? Liver Int. 2012;32:1333–1341.
6. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816, viii.
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
8. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
9. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
10. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–758.
11. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
12. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
13. Goodman, ZD Afdhal NH, Buti MM, et al. Morphometric assessment of quantitative collagen and liver fibrosis in patients with chronic hepatitis B treated for up to five years with tenofovir disoproxil fumarate (TDF). Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–5, 2013; Washington, DC.
14. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143.
15. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.
16. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435.
17. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–442.
18. Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A–H and its use in antiviral phenotyping assays. J Virol Methods. 2011;173:340–346.
19. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49:S28–S34.
20. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
21. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117.
22. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139:1207–1217.
23. Levrero M, Cimino L, Lampertico P, et al. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OptiB Italian Multicenter Prospective Open Label study. Presented at Annual Meeting of the American Association for the Study of Liver Diseases; October 29–November 2, 2010; Boston, MA, Abstract 138.
24. Hou JL, Gao ZL, Xie Q, et al. Continued use of tenofovir disoproxil fumarate monotherapy or switching from adefovir dipivoxil results in potent viral suppression and a favorable safety profile in Chinese patients with chronic hepatitis B. Presented at the Asian Pacific Association for the Study of the Liver Annual Meeting; March 12–15, 2014; Brisbane, Australia. Poster #847; 2014.